William Alden, MD, PhD | Medical Peptide & Fatty Acid Series
Sexual Health Peptides
By William Alden, MD, PhD | Medical Peptide, Regenerative & Fatty Acid Series
A small but important group of melanocortin peptides act on central pathways governing arousal and on peripheral pathways governing pigmentation. I approach this area with particular attention to what is FDA-approved, what is not, and why the unapproved parent compounds should not be treated as interchangeable with the approved agents.
Key Agents in This Class
Bremelanotide (PT-141, Vyleesi).
A melanocortin receptor agonist (primarily MC3R and MC4R) that activates central nervous-system pathways governing sexual arousal and desire in the hypothalamus. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Mechanism is entirely CNS-based rather than vascular.
Afamelanotide (Scenesse).
A synthetic α-MSH analog and MC1R agonist that stimulates eumelanin production. FDA-approved as a subcutaneous implant to increase pain-free light exposure in patients with erythropoietic protoporphyria (EPP), a rare phototoxic disorder.
Melanotan II.
A nonselective melanocortin agonist (MC1R/MC3R/MC4R) that affects both pigmentation and, via MC4R, sexual arousal. It is the parent compound from which bremelanotide was derived. It is not FDA-approved, has been marketed online, and occupies a regulatory gray zone after 2026 Category 2 removal; it is not a substitute for the approved agents.
Evidence and Regulatory Status
Bremelanotide and afamelanotide are FDA-approved for defined, evidence-supported indications. Melanotan II lacks approval, carries safety concerns (including uncontrolled pigmentation and potential systemic effects), and should not be regarded as equivalent to the approved melanocortin therapies. Compounding status remains unsettled pending further PCAC review.
Read more about this: [Reproductive Health: GnRH Agents and Fertility Peptides] and [Obstetric and Oxytocin Peptides].
Frequently Asked Questions
Is Melanotan II the same as the approved products?
No. It is an unapproved precursor compound with a broader receptor profile and different safety record. It is not a clinical substitute for FDA-approved bremelanotide or afamelanotide.
What is afamelanotide used for?
It is approved to reduce phototoxic reactions and increase pain-free light exposure time in erythropoietic protoporphyria.
How does bremelanotide differ from PDE5 inhibitors?
PDE5 inhibitors act peripherally on vascular smooth muscle to facilitate erection. Bremelanotide acts centrally on melanocortin pathways that govern desire and arousal; it is indicated for HSDD in premenopausal women, not for erectile dysfunction.
Clinical Perspective
The approved melanocortin agents demonstrate how a single receptor family can address very different clinical problems—central sexual desire on one hand and photoprotection on the other. The unapproved members of the family warrant genuine caution and clear patient counseling.
About the Author
William “Wes” Alden, MD, PhD, is a physician-scientist and internist whose career spans academic medicine, federal clinical research, community healthcare, and medical philanthropy. His work sits at the intersection of laboratory science and bedside care, and his writing consistently returns to one theme: regenerative and metabolic therapies deserve both open-minded use and rigorous scientific and regulatory scrutiny. This series surveys the major categories of therapeutic peptides and healthful fatty acids, one blog at a time, with an emphasis on honest evidence and clear regulatory status.
Important Disclosure and Disclaimer
This content is for general education and reflects Dr. Alden’s professional perspective. It is not medical advice and does not create a doctor-patient relationship. Individual results vary, and many agents discussed are not FDA-approved for the uses described. Several peptides are not FDA-approved and have an evolving federal compounding status; products labeled for research use only are never appropriate for use in people. Most fatty acids discussed are foods or dietary supplements and are not FDA-approved to treat any condition. Any peptide or compounded agent should be used only through a licensed provider, with appropriately sourced pharmaceutical-grade material. Readers should consult a qualified healthcare professional about their own situation before pursuing any treatment.
Educational content reflecting Dr. Alden’s professional perspective. Not medical advice. Several agents named are not FDA-approved and some have an evolving compounding status. See the full disclosure accompanying this series.

October 29, 2026
4 min read




Back to Blog